文献速递骨质疏松与钙磷/甲状旁腺

口服双膦酸盐药物假期对髋部骨折后死亡率的影响

Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项在澳大利亚维多利亚州开展的回顾性人群队列研究纳入365例髋部骨折前口服阿仑膦酸或利塞膦酸依从≥5年的患者,分析药物假期与骨折后死亡率的关系。结果显示,停用利塞膦酸1年(HR 2.37;95%CI 1.24-4.53)和2年(HR 3.08;95%CI 1.48-6.41)者骨折后死亡率升高,而停用阿仑膦酸未见升高或降低。作者认为规划药物假期时双膦酸盐类型可能是需考虑的因素。

要点

  • 停用利塞膦酸1年者髋部骨折后死亡率升高(HR 2.37;95%CI 1.24-4.53)。
  • 停用利塞膦酸2年者髋部骨折后死亡率升高(HR 3.08;95%CI 1.48-6.41)。
  • 停用阿仑膦酸1年或2年者骨折后死亡率未见升高或降低。

核心结论

  • 在依从口服双膦酸盐至少5年的人群中,停用利塞膦酸1年或2年者髋部骨折后死亡率更高,而停用阿仑膦酸者未见升高或降低;规划药物假期时双膦酸盐类型可能是需考虑的因素。

研究设计与样本

  • 回顾性、人群队列研究,纳入2014至2018年澳大利亚维多利亚州所有髋部骨折患者,要求髋部骨折前口服阿仑膦酸或利塞膦酸依从5年及以上。
  • 采用基于组的轨迹模型对5年良好依从后的双膦酸盐使用情况进行分组,主要结局指标为骨折后死亡率。
  • 共识别365例对口服阿仑膦酸/利塞膦酸良好依从(药物持有率≥80%)5年及以上的患者。

主要发现

  • 多数患者(69%)持续使用口服双膦酸盐直至因髋部骨折入院;17%已停药1年,14%已停药2年。
  • 停用利塞膦酸1年者骨折后死亡率更高(HR 2.37;95%CI 1.24-4.53)。
  • 停用利塞膦酸2年者骨折后死亡率更高(HR 3.08;95%CI 1.48-6.41)。
  • 停用阿仑膦酸1年者骨折后死亡率未见升高或降低(HR 0.59;95%CI 0.29-1.18)。
  • 停用阿仑膦酸2年者骨折后死亡率未见升高或降低(HR 1.05;95%CI 0.57-1.93)。

临床怎么用

  • 作者认为,规划药物假期时双膦酸盐类型可能是需考虑的因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Current clinical guidelines recommend a drug holiday after extended use of oral bisphosphonates. However, no studies have investigated the effect of drug holidays before hip fractures on postfracture mortality. OBJECTIVE: This work aimed to investigate the effect of a drug holiday on postfracture mortality in patients with extended use of oral bisphosphonates. METHODS: This retrospective, population-based cohort study took place among all patients with hip fractures in Victoria, Australia, from 2014 to 2018. Patients were adherent to oral alendronate or risedronate for 5 years or more prior to hip fracture. Group-based trajectory modeling categorized patients into different bisphosphonate usage after 5-year good adherence. The main outcome measure was postfracture mortality. RESULTS: We identified 365 patients with good adherence (medication possession ratio ≥80%) to oral alendronate/risedronate for 5 years or more. Most patients (69%) continued to use oral bisphosphonates until admission for hip fracture; 17% had discontinued for 1 year and 14% had discontinued for 2 years. Postfracture mortality was higher in patients who had discontinued risedronate for 1 year (hazard ratio [HR] 2.37; 95% CI, 1.24-4.53) and 2 years (HR 3.08; 95% CI, 1.48-6.41) prior to hip fracture. No increase or decrease in postfracture mortality was observed in patients who had discontinued alendronate for 1 year (HR 0.59; 95% CI, 0.29-1.18) or 2 years (HR 1.05; 95% CI, 0.57-1.93) prior to hip fracture. CONCLUSION: Postfracture mortality is higher in people who discontinue risedronate, but not alendronate, for 1 or 2 years after being adherent to treatment for at least 5 years. The type of bisphosphonate may be a factor to consider when planning drug holidays.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Leung MTY, Turner JP, Marquina C, et al. Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture. J Clin Endocrinol Metab. 2024. PMID: 38630464. doi:10.1210/clinem/dgae272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。